Exxonmobil Investment Management Inc Tx Lowers stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Exxonmobil Investment Management Inc Tx reduced its stake in Edwards Lifesciences Corp by 0.84% during the most recent quarter end. The investment management company now holds a total of 54,356 shares of Edwards Lifesciences Corp which is valued at $6,527,612 after selling 459 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Edwards Lifesciences Corp makes up approximately 0.14% of Exxonmobil Investment Management Inc Tx’s portfolio.

Other Hedge Funds, Including , Central Bank Trust Co added EW to its portfolio by purchasing 88 company shares during the most recent quarter which is valued at $10,568.Bnp Paribas Arbitrage Sa reduced its stake in EW by selling 10,360 shares or 56.17% in the most recent quarter. The Hedge Fund company now holds 8,084 shares of EW which is valued at $970,161.Washington Trust Bank boosted its stake in EW in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 103 shares of Edwards Lifesciences Corp which is valued at $12,361.Eqis Capital Management boosted its stake in EW in the latest quarter, The investment management firm added 1,789 additional shares and now holds a total of 18,692 shares of Edwards Lifesciences Corp which is valued at $2,243,227. Edwards Lifesciences Corp makes up approx 0.14% of Eqis Capital Management’s portfolio.

Edwards Lifesciences Corp opened for trading at $120.09 and hit $120.62 on the upside on Friday, eventually ending the session at $120.09, with a gain of 0.31% or 0.37 points. The heightened volatility saw the trading volume jump to 7,30,882 shares. Company has a market cap of $25,565 M.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.